Project Grant R21AI202154
Award Date 8/12/26
Completion Date 7/31/28
Dollars Obligated $235K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98109, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Northwestern University $480,000 on August 13, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify the phenotypic, genetic, and epigenetic traits that predispose certain Salmonella serovars to chronic infection. The project addresses the clinical challenge that non-typhoidal Salmonella causes persistent infections resistant to host immunity and antibiotic therapy, yet the mechanisms driving...
- The National Institute of Allergy and Infectious Diseases awarded the Institute For Systems Biology $940,934 on June 12, 2026, for research on canonical and non-canonical phosphorylation events in bacterial pathogens under CFDA 93.855 (Allergy and Infectious Diseases Research). The project develops and applies engineered affinity reagents called phosphopeptide "superbinders" to interrogate phosphorylation in bacterial pathogens. Traditional immobilized metal affinity chromatography...
- The National Institute of Allergy and Infectious Diseases awarded The Leland Stanford Junior University $771,210 on February 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate Salmonella persistence in mammalian tissues. The research examines how Salmonella enterica serovar Typhimurium (STM) maintains persistent infection in mesenteric lymph nodes and identifies host immune pathways amenable to preventive and therapeutic intervention. The work...
- The National Institute of Allergy and Infectious Diseases awarded New York University $254,250 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to test the epigenetic basis and evolutionary generality of bacterial persistence in Staphylococcus aureus. The research examines how bacteria survive antibiotic treatment without genetic changes—a phenomenon distinct from drug resistance and drug tolerance. The project builds on preliminary findings that...
- The National Institute of Allergy and Infectious Diseases awarded $596,318 to The University of Texas Southwestern Medical Center on February 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to define virulence factor functions in Salmonella enterica using minimal pathogen genomes. The research characterizes how a small network of SPI-2 type III secretion system effector proteins coordinate membrane scission of the Salmonella-containing vacuole (SCV) and...
- The National Institute of Allergy and Infectious Diseases awarded the University of Vermont & State Agricultural College $245,725 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify genes in Salmonella enterica required for colonization of epithelial cells in the large intestine and gallbladder. The research uses an ordered barcoded library of single gene deletion mutants in S. enterica serovar Typhimurium to perform a genome-scale...
- The National Institute of Allergy and Infectious Diseases awarded the University of Wisconsin–Madison $427,625 on February 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855, Project Grant R21AI190266). The award funds investigation of the role of YeiH protein in Salmonella pathogenesis, specifically its function in sulfite stress resistance. Non-typhoidal Salmonella enterica causes bacterial foodborne gastroenteritis and represents the leading cause of death...
- The National Institute of Allergy and Infectious Diseases awarded the University of California, Davis $412,206 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to compare adaptive immune responses across different Salmonella serovars. The research validates a new mouse model permissive for Salmonella typhi infection to enable side-by-side analysis of typhoidal and non-typhoidal disease. The work addresses a gap in vaccine development: while conjugate...
- The National Institute of Allergy and Infectious Diseases awarded $267,000 to the Benaroya Research Institute at Virginia Mason on June 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research into circulating and mucosal immune cell populations affected by therapeutic interleukin-23 blockade in Crohn's disease patients treated with risankizumab. The project will quantify and characterize TH17 cells, mucosa-associated invariant T cells,...
- The National Institute of Allergy and Infectious Diseases, under the Department of Health and Human Services, awarded Temple University $198,125 on August 18, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds investigation of how Salmonella biofilms trigger reactive arthritis following enteric infection. Research will examine the role of curli, a Salmonella protein comprising 85 percent of the biofilm matrix, in forming stable complexes with DNA that...